Nick Woolf
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Nick Woolf
Nick Woolf is an accomplished biotechnology professional with over 25 years of experience in the investment banking and life sciences industry in Australia and internationally. He has a strong track record in structuring, negotiating and executing successful alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organisations.
Mr Woolf is also a qualified accountant, a Graduate of the Australian Institute of Company Directors, holds a Graduate Certificate in Management (with Distinction ) from the Australian Institute of Business, and has a BA (Honours) and MA in Chemistry from Oxford University.
Mr Woolf is also a qualified accountant, a Graduate of the Australian Institute of Company Directors, holds a Graduate Certificate in Management (with Distinction ) from the Australian Institute of Business, and has a BA (Honours) and MA in Chemistry from Oxford University.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 367th | Advanced Braking Technology | 23% | 29% |
| 636th | PYC Therapeutics | 3% | 27% |
| 806th | DTI Group | -5% | -15% |
| 1278th | K2fly | -37% | -8% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 87th |  | PYC Therapeutics | $15.8m |
| 90th |  | GreenHy2 | $15.0m |
| 91st | | K2fly | $14.8m |
| 93rd | | Advanced Braking Technology | $14.7m |
| 94th | | DTI Group | $13.3m |
201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in Research a driver for cannabis | 15 Dec 2020 |
| NEWS: Tagged in Phylogica appoints chief scientist as new CEO | 15 Dec 2020 |
| NEWS: Tagged in Hopkins chief at Phylogica | 15 Dec 2020 |
| NEW ROLE: Chief Executive, AusCann Group Holdings | 05 Aug 2020 |
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Chief Executive | | 2020 - 2021 | 154 |
| Chief Business Officer | | 2013 - 2018 | 974 |
| Non-Executive Director | | 2010 - 2013 | 87 |
| Senior Biotech Analyst (London) | | 1995 - 1997 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| PYC Therapeutics | 04 Apr 2012 | Bought | 6,000,000 | OtherShares allotted pursuant to long term incentive share plan | ||
| PYC Therapeutics | 12 Jan 2012 | Bought | 250,000 | $0.04 | $9,775 | On-market trade |
| PYC Therapeutics | 16 May 2011 | Bought | 847,456 | $0.06 | $50,000 | OtherParticipation in placement |
| PYC Therapeutics | 04 Oct 2010 | Bought | 300,000 | $0.05 | $14,850 | On-market trade |
| PYC Therapeutics | 22 Sep 2010 | Bought | 300,000 | $0.05 | $14,910 | On-market trade |
Powered by Morningstar ®
